You are here

Experts Discuss Key Issues in Lung Cancer Testing

Watch expert pathologists and oncologists discuss key issues in the diagnosis and molecular testing of lung cancer

Listen to expert opinion from 2015

Pfizer Oncology 2015 Virtual Forum NSCLC: The Continuum of Care for Patients with ALK-positive NSCLC

Expert panel: Professor Jean-Charles Soria, Dr Santiago Ponce, Professor Aleš Ryška, Professor Jürgen Wolf, Professor Federico Cappuzzo, Dr Maximilian Hochmair, Dr Jens Benn Sørensen

Pfizer Oncology 2015 Virtual Forum NSCLC: The Continuum of Care for Patients with ALK-positive NSCLC

Expert panel: Professor Jean-Charles Soria, Dr Santiago Ponce, Professor Aleš Ryška, Professor Jürgen Wolf, Professor Federico Cappuzzo, Dr Maximilian Hochmair, Dr Jens Benn Sørensen

ALK testing case study 1Dr Jens Benn Sørensen, National Copenhagen University Hospital, Denmark, describes the diagnostic
ALK testing case study 2Dr Maximillian Hochmair, Otto Wagner Hospital, Vienna, Austria, describes the biopsy and pathology
ALK testing case study 3Professor Federico Cappuzzo, IRST-AUSL della Romagna, Ravenna,Italy, describes the case of a patient
Who to test for ALK?The panel provides their recommendations as to which patients should be tested for ALK.
ALK testing turnaround timesThe panel discuss the optimal turnaround time of ALK test results.
Which NSCLC subtypes to test for ALK?The panel discuss testing for ALK in different NSCLC histologic subtypes.
Borderline ALK FISH resultsThe panel discuss the interpretation of borderline ALK FISH results.
Blood-based ALK testingThe panel discuss ALK testing in blood-based specimens.
Cytological ALK testingThe panel discuss testing for ALK with cytological specimens.
ALK testing: pre-analytical considerationsThe panel discuss some of the pre-analytical considerations for ALK testing.